Phase II trial of combined high-dose-rate brachytherapy and external beam radiotherapy for adenocarcinoma of the prostate: preliminary results of RTOG 0321
about
High dose rate prostate brachytherapy: an overview of the rationale, experience and emerging applications in the treatment of prostate cancerStereotactic Body Radiation Therapy for Prostate Cancer: What is the Appropriate Patient-Reported Outcome for Clinical Trial Design?Credentialing for participation in clinical trials.Significant association of brachytherapy boost with reduced prostate cancer-specific mortality in contemporary patients with localized, unfavorable-risk prostate cancer.Development and implementation of a remote audit tool for high dose rate (HDR) Ir-192 brachytherapy using optically stimulated luminescence dosimetry.Intensity-Modulated Radiation Therapy with Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: A Report on 3-Year Toxicity.Dosimetric analysis of radiation therapy oncology group 0321: the importance of urethral dose.Do theoretical potential and advanced technology justify the use of high-dose rate brachytherapy as monotherapy for prostate cancer?Combining theoretical potential and advanced technology in high-dose rate brachytherapy boost therapy for prostate cancer.Progress and controversies: Radiation therapy for prostate cancer.A review of rectal toxicity following permanent low dose-rate prostate brachytherapy and the potential value of biodegradable rectal spacers.NPIP: A skew line needle configuration optimization system for HDR brachytherapy.Comparison of IPSA and HIPO inverse planning optimization algorithms for prostate HDR brachytherapy.Hypofractionated SBRT versus conventionally fractionated EBRT for prostate cancer: comparison of PSA slope and nadir.Outcomes of hypofractionated stereotactic body radiotherapy boost for intermediate and high-risk prostate cancer.High-dose-rate brachytherapy combined with hypofractionated external beam radiotherapy for men with intermediate or high risk prostate cancer: analysis of short- and medium-term urinary toxicity and biochemical controlClass solution in inverse planned HDR prostate brachytherapy for dose escalation of DIL defined by combined MRI/MRSI.Comparison of Oncentra® Brachy IPSA and graphical optimisation techniques: a case study of HDR brachytherapy head and neck and prostate plans.Improving plan quality and consistency by standardization of dose constraints in prostate cancer patients treated with CyberKnife.IPIP: A new approach to inverse planning for HDR brachytherapy by directly optimizing dosimetric indices.High-Dose Robotic Stereotactic Body Radiotherapy in the Treatment of Patients With Prostate Cancer: Preliminary Results in 26 Patients.Outcomes of Asian patients with localized prostate cancer treated with combined intensity modulated radiation therapy (IMRT) and high dose rate (HDR) brachytherapy: A single institution experience.Multisource Rotating Shield Brachytherapy Apparatus for Prostate Cancer.HDR brachytherapy combined with external beam radiation for localised prostate cancer: early experience from the Sydney Cancer Centre.Quantifying the effect of seed orientation in postplanning dosimetry of low-dose-rate prostate brachytherapy.Adaptation of the CVT algorithm for catheter optimization in high dose rate brachytherapy.Evaluation of tolerance and toxicity of high-dose-rate brachytherapy boost combined with interstitial hyperthermia for prostate cancer.Evidenced-based clinical practice guideline for prostate cancer (summary: Japanese Urological Association, 2016 edition).Dose tolerance limits and dose volume histogram evaluation for stereotactic body radiotherapy.High dose-rate brachytherapy in the treatment of prostate cancerComparison of high-dose (86.4 Gy) IMRT vs combined brachytherapy plus IMRT for intermediate-risk prostate cancer
P2860
Q26824608-A6310604-F59C-4A8C-BB03-D4BB26ADE800Q35233601-7ACB9D38-2D04-4387-848A-646C778A8467Q36488383-96F8F705-4C94-4B47-ABC3-C80089D7A298Q36802277-7B965FB9-83E7-4E58-B32B-B2B6C7022765Q37288578-301A12A0-6EF5-434C-9B94-D3E1EA903201Q37627132-9D6FFBC1-C771-482A-98E2-783CB9C7F971Q37724784-92BCA39B-98A0-44BD-B2CD-B2F5331D6310Q38152466-D17F28DB-21E8-461A-9EB0-64B6478FB994Q38160244-BBDBBFCB-966F-4425-8CB2-695B89498BB8Q38252429-38626784-693C-4C0E-9A75-E937DD78D0B4Q38357722-79B3CB6A-1DD7-4B01-BE68-598492E22CC5Q38779286-9A345C6D-8349-42D4-BBF1-3A41AF7B02E7Q41706903-789987FB-5006-4E48-A044-CE371D638108Q41952611-064EB17A-79D8-4DD3-AEFF-6FFE51E9AE81Q41985869-681F234A-CD29-4CB7-BBA8-543FBD7BB2D0Q42012657-C9CFBEE0-F097-43C6-8D50-9175D7445927Q42412315-D9084D25-18A0-4CA7-B327-FA21614D20A4Q42532900-B535C634-D3D2-4316-9D80-63500313FCD1Q43422976-BA2DD73A-2FDE-4A7E-AF26-0D046827FDD7Q43555409-C6DE6ABA-A552-4624-BD7A-C143D0B5EB46Q46801852-2628F15E-FF2D-458B-BE51-3568F37358CAQ47420362-F63485A0-1FDE-4659-82F7-77E1C179B417Q47751134-24C875CB-8B65-4523-8CEF-6EA78532EA78Q48455880-DF8DEE92-519E-4B99-B632-36C8D5E00F0DQ50630763-141D207F-E665-4690-9755-3959F2E258D9Q51135001-456093D9-B8A4-4098-8617-AB460761B22BQ53127875-0FE41119-54FE-4FC5-884A-CAAEE8DCEF2AQ53734447-06348098-25C7-4432-9CAA-BD2F778A5A94Q54974398-8B0D0AAB-C6F4-4EB6-9CEB-57164F0CD53CQ57112470-D36B2EF5-C544-42C6-89E1-616A7333E569Q57860471-523C01B4-DEF3-4A1C-A94F-3F2091E1719C
P2860
Phase II trial of combined high-dose-rate brachytherapy and external beam radiotherapy for adenocarcinoma of the prostate: preliminary results of RTOG 0321
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Phase II trial of combined hig ...... eliminary results of RTOG 0321
@en
type
label
Phase II trial of combined hig ...... eliminary results of RTOG 0321
@en
prefLabel
Phase II trial of combined hig ...... eliminary results of RTOG 0321
@en
P2093
P2860
P921
P1476
Phase II trial of combined hig ...... eliminary results of RTOG 0321
@en
P2093
Eric Vigneault
Geoffrey Ibbott
Howard Sandler
I-Chow Hsu
James Purdy
Jean Pouliot
Joycelyn Speight
Katsuto Shinohara
Kyounghwa Bae
Robert Ivker
P2860
P304
P356
10.1016/J.IJROBP.2009.08.048
P407
P577
2010-03-06T00:00:00Z